The important role of Hexvix®/ Cysview® in the detection and management of bladder cancer highlighted at the BLADDR 2018 congress

Published: 24 September 2018

The BLADDR 2018 Congress took place in Madrid September 20-21. It is the 3rd Global Congress on Bladder Cancer and a major educational multidisciplinary event purely focusing on bladder cancer attended by specialists from all over the world.

Dr. Ashish Kamat, from the University of Texas MD Andersson Cancer Center, addressed the key role of Blue Light Cystoscopy (BLC™) with Hexvix/Cysview in his opening lecture "Overcoming barriers to progress in NMIBC - Where are we in 2018 and where will we be in 5 years?" and challenged the current gold standard when it comes to tumor detection to bring the management of bladder cancer from the past to future standards. Read more here:

Dr. Siamak Daneshmand, from the University of Southern California, gave a presentation on "Contemporary advances in the endoscopic evaluation and diagnosis of bladder cancer", demonstrating how BLC with Hexvix/Cysview change the management of bladder cancer patients, including in the follow up with flexible cystoscopy. Dr. Daneshmand reviewed the large body of evidence showing increased detection rates and reduced rates of recurrence and progression in Non-Muscle Invasive Bladder Cancer. He also summarized the data from the recently published Phase III U.S. trial on in-office use of BLC with Cysview for surveillance cystoscopy which demonstrated similar increased detection rates for both papillary tumors and carcinoma in-situ (CIS).

MD Marie Schmidt Erikson, Herlev and Gentofte Hospital, Copenhagen presented a poster on future perspectives for outpatient management including BLC guided diode laser treatment demonstrating the opportunities for completion of treatment in a minor procedure in the awake patient.

News and events